Table 2.
Baseline patient demographics and disease characteristics in the two groups of patients with a high risk of recurrence.
| Variable | Control group (n=164) | Sorafenib group (n=146) | P value |
| Age (years) | 51.0 (24.0–82.0) | 52.7 (21.0–74.0) | 0.0627 |
| Female/male | 25/139 | 22/124 | 0.6630 |
| PLT (109/L) | 160.83 (38.00–476.00) | 147.50 (30.00–458.00) | 0.1707 |
| TBIL (μmol/L) | 17.61 (0.00–391.00) | 17.23 (3.80–71.20) | 0.1373 |
| ALT (U/L) | 48.65 (8.00–279.00) | 60.73 (8.00–781.00) | 0.4658 |
| AST (U/L) | 42.89 (13.00–345.00) | 65.95 (30.00–1412.00) | 0.0352 |
| Neutrophil (109/L) | 2.63 (0.86–40.00) | 3.56 (1.29–58.40) | 0.5128 |
| Lymphocyte (109/L) | 1.50 (0.30–7.00) | 1.44 (0.46–30.60) | 0.4170 |
| TP (g/L) | 69.18 (26.00–87.00) | 66.54 (26.00–84.90) | 0.3404 |
| ALB (g/L) | 41.19 (20.40–73.10) | 41.10 (5.40–73.10) | 0.0070 |
| GGT (U/L) | 90.14 (12.00–625.00) | 99.10 (14.00–1319.00) | 0.0652 |
| Differentiation | 0.8405 | ||
| Poor | 85 (51.83) | 74 (50.69) | |
| Moderate-well | 79 (48.17) | 72 (49.31) | |
| Etiology | 0.9563 | ||
| Hep B | 143 (84.62) | 127 (86.99) | |
| Other | 21 (15.38) | 19 (13.01) | |
| AFP | 0.4660 | ||
| Low (serum AFP ≤500) | 91 (55.49) | 87 (59.59) | |
| High (serum AFP >500) | 73 (44.51) | 59 (40.41) | |
| Satellites | 37 (25.34) | 43 (29.45) | 0.1662 |
| Cirrhosis | 0.5322 | ||
| Yes | 88 (53.6) | 80 (54.79) | |
| No | 76 (46.4) | 66 (45.21) | |
| Tumor size (cm), median (range) | 8.69 (5.00–20.00) | 8.96 (5.00–25.00) | 0.5331 |
| Tumor number | 0.9908 | ||
| One | 143 (87.19) | 128 (87.68) | |
| Two | 13 (7.93) | 11 (7.53) | |
| More | 8 (4.88) | 7 (4.79) | |
| MVI (≥1) | 82 (50) | 79 (54.11) | 0.4953 |
| Child–Pugh class, n (%) | 0.1815 | ||
| A | 159 (96.95) | 144 (98.63) | |
| B | 5 (3.05) | 2 (1.37) | |
| BCLC stage, n (%) | 0.2837 | ||
| B | 134 (81.71) | 126 (86.30) | |
| C | 30 (18.29) | 20 (13.7) | |
| GS and Arg1 in HCC | 0.6122 | ||
| GS−Arg1− | 19 (17.68) | 22 (15.07) | |
| GS−Arg1+ | 29 (17.68) | 19 (13.01) | |
| GS+Arg1− | 66 (40.24) | 60 (41.10) | |
| GS+Arg1+ | 50 (30.48) | 45 (30.82) |
Data are presented as n (%) or median (interquartile range). ALB: Albumins; ALT: Alanine aminotransferase; AST: Aminotransferase; AFP: Alpha-fetoprotein; Arg1: Arginase 1; BCLC: Barcelona Clinic Liver Cancer; GGT: Glutamyltransferase; GS: Glutamine synthetase; GS−: GS negative; GS+: GS positive; HCC: Hepatocellular carcinoma; MVI: Microvascular invasion; PLT: Platelet count; TBIL: Total bilirubin; TP: Total protein.